Methods of using an agonistic antibody human tumor necrosis factor receptor (TR17)
US6969519B2 · kind B2 · utility
4Cited by
1References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 25, 2001 |
| Grant date | Nov 29, 2005 |
| Priority date | — |
| Expiry date | Apr 12, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a novel protein, TR17, which is a member of the tumor necrosis factor (TNF) receptor superfamily. In particular, isolated nucleic acid molecules are provided encoding the human TR17. TR17 polypeptides are also provided as anti TR17 antibodies and vectors, host cells and recombinant methods for producing the same. The invention further relates to methods of killing cells using the antibodies of the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.